• 1
    Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51(Suppl. 1): 5967.
  • 2
    Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990; 99: 34551.
  • 3
    Pipkin GA, Mills JG. Onset of action of antisecretory drugs: beneficial effects of a rapid increase in intragastric pH in acid reflux disease. Scand J Gastroenterol Suppl 1999; 230: 38.
  • 4
    Sjostedt S, Sagar M, Lindberg G, Wikstrom B, Nord CE, Seensalu R. Prolonged and profound acid inhibition is crucial in Helicobacter pylori treatment with a proton pump inhibitor combined with amoxicillin. Scand J Gastroenterol 1998; 33: 3943.
  • 5
    Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997; 272: 22 438 – 46.
  • 6
    Kromer W, Kruger U, Huber R, Hartmann M, Steinijans VW. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology 1998; 56: 5770.
  • 7
    Röhss K, Hasselgren G, Hendenstrom H. Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci 2002; 47: 9548.
  • 8
    Bruley Des Varannes S, Levy P, Lartigue S, Dellatolas F, Lemaire M, Galmiche JP. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers. Aliment Pharmacol Ther 1994; 8: 30914.
  • 9
    Dammann HG, Fuchs W, Richter G, Burkhardt F, Wolf N, Walter TA. Lansoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion. Aliment Pharmacol Ther 1997; 11: 35964.
  • 10
    Newton M, Burnham WR, Kamm MA. Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis. Eur J Gastroenterol Hepatol 1998; 10: 7538.
  • 11
    Thoring M, Hedenstrom H, Eriksson LS. Rapid effect of lansoprazole on intragastric pH: a crossover comparison with omeprazole. Scand J Gastroenterol 1999; 34: 3415.
  • 12
    Tolman KG, Sanders SW, Buchi KN, Karol MD, Jennings DE, Ringham GL. The effects of oral doses of lansoprazole and omeprazole on gastric pH. J Clin Gastroenterol 1997; 24: 6570.
  • 13
    Dammann HG, Burkhardt F. Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion. Eur J Gastroenterol Hepatol 1999; 11: 127782.
  • 14
    Hartmann M, Theiss U, Huber R, et al. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment Pharmacol Ther 1996; 10: 35966.
  • 15
    Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998; 12: 107989.
  • 16
    Huang JQ, Goldwater DR, Thomson AB, et al. Acid suppression in healthy subjects following lansoprazole or pantoprazole. Aliment Pharmacol Ther 2002; 16: 42533.
  • 17
    Meier R, Wolf A, Wettstein A, Drewe J, Messmer H. The effect of a single dose of a proton pump inhibitor on gastric acidity in volunteers. Gut 2000; 47(Suppl. 3): A81(Abstract).
  • 18
    Gardner JD, Perdomo C, Sloan S, et al. Integrated acidity and rabeprazole pharmacology. Aliment Pharmacol Ther 2002; 16: 45564.
  • 19
    Bauerfeind A, Cilluffo T, Emde C. Antacids revisited: how do they react with food in vivo? Gastroenterology 1986; 90: 1340.
  • 20
    Brummer RJ, Geerling BJ, Stockbrugger RW. Initial and chronic gastric acid inhibition by lansoprazole and omeprazole in relation to meal administration. Dig Dis Sci 1997; 42: 21327.
  • 21
    Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. PPIs: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther 2000; 14: 126772.
  • 22
    Bergstrand R, Grind M, Nyberg G, Olofsson B. Decreased oral bioavailability of lansoprazole in healthy volunteers when given with a standardised breakfast. Clin Drug Invest 1995; 9: 6771.
  • 23
    Logan RP. Urea breath tests in the management of Helicobacter pylori infection. Gut 1998; 43(Suppl. 1): S4750.
  • 24
    Pilbrant A. Pharmaceutical considerations. In: OlbeL, ed. Proton Pump Inhibitors. Basle: Birkhaus, 2001: 16172.
  • 25
    Saitoh T, Watanabe Y, Kubo Y, et al. Intragastric acidity and circadian rhythm. Biomed Pharmacother 2001; 55(Suppl. 1): 138s141s.
  • 26
    Baisley K, Warrington S, Tejura B, Morocutti A, Miller N. Rabeprazole 20 mg compared with esomeprazole 40 mg in the control of intragastric pH in healthy volunteers. Gut 2002; 50(Suppl. ii): A63(Abstract 229).
  • 27
    Warrington S, Baisley K, Boyce M, et al. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment Pharmacol Ther 2002; 16: 13017.
  • 28
    Scott LJ, Dunn CJ, Mallarkey G, Sharpe M. Esomeprazole: a review of its use in management of acid-related disorders. Drugs 2002; 62: 150338.
  • 29
    Prakash A, Faulds D. Rabeprazole. Drugs 1998; 55: 2617.
  • 30
    Landes BD, Petite JP, Fluovat B. Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet 1995; 28: 45870.
  • 31
    Huber R, Hartmann M, Bliesath H, et al. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 1996; 34: 18594.
  • 32
    Andersson T, Hassan-Alin M, Hasselgren G, et al. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001; 40: 41126.
  • 33
    Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis –– a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999; 13: 90714.
  • 34
    Earnest DL, Robinson M. Treatment advances in acid secretory disorders: the promise of rapid symptom relief with disease resolution. Am J Gastroenterol 1999; 94(Suppl. 11): S1724.
  • 35
    Barth J, Hahne W. Rabeprazole-based therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther 2002; 16(Suppl. 1): 313.
  • 36
    Hawkey C, Atherton J, Treichel H, et al. Rabeprazole vs. omeprazole in 7-day, triple therapy H. pylori eradication regimens for peptic ulcer. Gastroenterology 2001; 120: 581(Abstract).
  • 37
    Vakil N, Schwartz HJ, Lanza FL, et al. A prospective, controlled, randomized trial of 3-, 7-, and 10-day rabeprazole-based triple therapy for H. pylori eradication in the USA. Gastroenterology 2002; 122: 551(Abstract).